bFGF (119-126)
Based on 5 publication(s) in Google Scholar
bFGF (119-126) is a ligand of bFGF. The complex formed by bFGF (119-126) and bFGF can bind to FGFR1, while inhibiting the bFGF-FGFR1 interaction, FGFR1 phosphorylation and downstream signaling pathways. Therefore, bFGF (119-126) induces cell apoptosis and inhibits cell proliferation, migration, angiogenesis and metastasis. When conjugated with a carrier, bFGF (119-126) enhances cellular uptake via FGFR-mediated endocytosis and serves as an effective FGFR-targeted ligand. When used in combination with ultrasound and Doxorubicin (HY-15142A), bFGF (119-126) significantly enhances the inhibitory effect on tumors. bFGF (119-126) is applicable to research related to lung cancer, breast cancer, glioblastoma and ovarian cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.93%
- CAS No.: 152051-61-1
- Formule: C44H76N14O12
- Masse moléculaire:993.16
-
Stockage:
Sealed storage, away from moisture and light.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) bFGF (119-126)
More
Activité biologique
FITC-bFGFp-BSA, a peptide derived from bFGF (119-126), at 50 μg/mL for 2 h, is significantly internalized by NIH3T3 cells with high FGFRs expression, and this internalization effect is significantly inhibited by excess free bFGFp[2].
Cyclic peptide BGF1 derived from bFGF (119-126) (0.22~1.8 mM; 48 h) dose-dependently inhibits the proliferation of HUVECs, 4T1, U87 and SKOV3 cells induced by 20 ng/mL bFGF, with IC50 values of 1.09 μM, 1.27 mM, 0.65 μM and 0.18 μM for different cells, respectively. The linear peptide at 3 mM shows no such proliferation-inhibiting effect[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NIH3T3 mouse embryonic fibroblast cells
-
Concentration:0.1 μM, 1.0 μM free bFGFp; 0.72 μg/mL, 7.2 μg/mL bFGFp-BSA; 4 μM, 40 μM bFGFp-modified liposomes
-
Incubation Time:72 h
-
Result:Neither the free bFGFp, bFGFp-BSA conjugate, nor bFGFp-modified liposomes altered the proliferation and viability of NIH3T3 cells, regardless of the presence or absence of 1 nM bFGF in the culture medium.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:6–8 weeks-old female BALB/c mice with 4T1 murine mammary carcinoma subcutaneous metastatic tumor model, transplanted with 4T1 tumor fragments subcutaneously on the right flank, treatment initiated when tumor volume reached ~150 mm3 (14 days after tumor implantation)[3]
-
Dosage:Cyclic peptide BGF1 at 2 mg/kg and 10 mg/kg, linear peptide BGF2 at 2 mg/kg and 10 mg/kg
-
Administration:all via intraperitoneal (i.p.) injection daily for 3 weeks; Avastin at 5 mg/kg via intravenous (i.v.) injection once every 14 days (total 2 times); PBS as vehicle control via daily i.p. injection. All agents were dissolved in phosphate-buffered saline
-
Result:The 10 mg/kg BGF1 treatment group achieved ~70% tumor growth inhibition on day 34 after implantation, which was significantly more effective than the Avastin group, while the 2 mg/kg BGF1 group showed ~14% tumor growth inhibition.
Neither 2 mg/kg nor 10 mg/kg of linear peptide BGF2 showed significant inhibitory effect on tumor growth compared with the PBS control group. All mice in the 10 mg/kg BGF1 group survived until the end of the experiment, while the mortality rate was 29% in the PBS group, 86% in the Avastin group, 29% in the 2 mg/kg BGF1 group, and 29% in the BGF2 groups.
Mice in the BGF1 treatment groups gained weight during the experiment, while the Avastin group showed significant weight loss.
Chemical Information
-
CAS No. 152051-61-1
-
Appearance Solid
-
Masse moléculaire 993.16
-
Formule C44H76N14O12
-
Color White to off-white
-
Sequence
Lys-Arg-Thr-Gly-Gln-Tyr-Lys-Leu
-
Sequence Shortening
KRTGQYKL
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture and light
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
J Hazard Mater
Integrating scRNA-seq to explore offspring neurodevelopmental toxicity induced by Cyfluthrin exposure during pregnancy: A fate decision for NSCs. [Abstract]2025 Apr 7:492:138205. PMID: 40209410 -
Research (Wash D C)
Lactate-Induced Mitochondrial Calcium Uptake 3 Aggravates Myocardial Ischemia-Reperfusion Injury by Promoting Neutrophil Extracellular Trap Formation. [Abstract]2025 May 30:8:0705. PMID: 40452820 -
Oncogene
TRIM21-mediated ubiquitination of SIX2 attenuates breast cancer stemness via LGSN suppression. [Abstract]2025 Sep 15. PMID: 40954199 -
Int J Mol Sci
The Retinoic-Acid-Related Orphan Receptor Alpha May Be Highly Involved in the Regulation of Seasonal Hair Molting. [Abstract]2025 Feb 13;26(4):1579. PMID: 40004044 -
Future Sci OA
The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway. [Abstract]2026 Dec;12(1):2615619. PMID: 41562160
Solvant et solubilité
H2O : ≥ 100 mg/mL (100.69 mM)
DMSO : 50 mg/mL (50.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Terada T, et al. Basic fibroblast growth factor-binding peptide as a novel targeting ligand of drug carrier to tumor cells. J Drug Target. 2006;14(8):536-545. [Content Brief]
[2]. Wu Y, et al. Preparation and antitumor activity of bFGF-mediated active targeting doxorubicin microbubbles. Drug Dev Ind Pharm. 2013;39(11):1712-1719. [Content Brief]
[3]. Allahmoradi H, et al. Anti-tumor and anti-metastatic activity of the FGF2 118-126 fragment dependent on the loop structure. Biochem J. 2022;479(12):1285-1302. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 1.0069 mL | 5.0344 mL | 10.0689 mL | 25.1722 mL |
| 5 mM | 0.2014 mL | 1.0069 mL | 2.0138 mL | 5.0344 mL | |
| 10 mM | 0.1007 mL | 0.5034 mL | 1.0069 mL | 2.5172 mL | |
| 15 mM | 0.0671 mL | 0.3356 mL | 0.6713 mL | 1.6781 mL | |
| 20 mM | 0.0503 mL | 0.2517 mL | 0.5034 mL | 1.2586 mL | |
| 25 mM | 0.0403 mL | 0.2014 mL | 0.4028 mL | 1.0069 mL | |
| 30 mM | 0.0336 mL | 0.1678 mL | 0.3356 mL | 0.8391 mL | |
| 40 mM | 0.0252 mL | 0.1259 mL | 0.2517 mL | 0.6293 mL | |
| 50 mM | 0.0201 mL | 0.1007 mL | 0.2014 mL | 0.5034 mL | |
| H2O | 60 mM | 0.0168 mL | 0.0839 mL | 0.1678 mL | 0.4195 mL |
| 80 mM | 0.0126 mL | 0.0629 mL | 0.1259 mL | 0.3147 mL | |
| 100 mM | 0.0101 mL | 0.0503 mL | 0.1007 mL | 0.2517 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz